AzTrials
AzTrials

Speech Intelligibility Intervention in Down SyndromeNCT05016037

Predictors of Speech Ability in Down Syndrome

A study testing Lexically based speech recast in people with Speech Intelligibility Intervention in Down Syndrome, run by Vanderbilt University Medical Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Speech is a critical aspect of the human experience and usually develops in a "seemingly automatic process that continues from birth through adolescence and underlies many related abilities" (e.g., language and reading, see National Academy of Medicine Report on Speech and Language Disorders, 2016). Read more about this study

Who is it for?
Ages 4 to 17 years
What is being tested?
Lexically based speech recast
Could I receive a placebo?
No, everyone receives an active treatment
How many people
18 participants
Where
1 siteUnited States
Study dates
14 Feb 2022to 30 Apr 2025
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 4 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • previous medical identification of Down Syndrome
  • chronological age 4-17 years
  • regular use of 3-word utterances (ascertained via parent report during screening and confirmed during assessments)
  • pass a hearing screening at the time of enrollment in the project. All will pass a hearing screening (25 dB @1000, 2000, 4000 Hz).

Who cannot join

  • A history of or parent report of
  • seizures,
  • diagnosed ADHD,
  • apraxia secondary to a diagnosed neurological disorder
  • Autism Spectrum Disorder (Autism Diagnostic Observation Scale-2nd Edition score above the ASD cut-off) or
  • severe disruptive behavior that would prevent participation in testing or treatment.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • VUMC Bill Wilkerson Center

    Nashville, Tennessee, 37232

Other trials in United States

About this study

Speech is a critical aspect of the human experience and usually develops in a "seemingly automatic process that continues from birth through adolescence and underlies many related abilities" (e.g., language and reading, see National Academy of Medicine Report on Speech and Language Disorders, 2016). Many individuals with Down Syndrome (Trisomy 21, DS) struggle to communicate and participate more fully in human communication and educational learning experiences because their speech is difficult to understand. The purpose of the proposed project was to measure speech-articulation accuracy and speech intelligibility, and their proposed primary predictors at study entry in 16 children with DS age 4;0 to 17;11). A validated treatment, speech recast intervention (see Yoder, Camarata \& Woynaroski, 2016) was used to drive growth in speech intelligibility as a means of evaluating changes in potential sequelae of change. This study included measures of speech-articulation accuracy, and speech-prosody skills as predictors of speech intelligibility growth in DS.

Read the detailed description

In most children, speech development progresses in a "seemingly automatic manner that continues from birth through adolescence"1 and supports related communication and reading abilities. But many individuals with Down Syndrome (DS, about 1 in 700 births in the US) struggle to acquire speech and participate more fully in human communication and gain access to learning experiences, in part, because their speech is often difficult to understand. This persistent speech disorder arises because people with DS must acquire and produce speech using structurally-different articulators and poor speech oral-motor abilities. Moreover, there is considerable variability in the speech intelligibility of people with DS and it is unclear why some people with DS communicate relatively proficiently whereas others are unable to clearly communicate.

The Investigator's recent research provides a unique combination of findings that, when integrated into a prospective project, can potentially provide new insights into how people with DS improve speech intelligibility. This assertion is grounded in the long-standing and replicated finding that speech intelligibility in DS is not strongly correlated with nor solely attributable to measures of phoneme production, so that improvements in intelligibility must rely not only improvements in speech accuracy (phoneme production) but also upon changes in "nonphonemic" factors such as cognitive-linguistic parameters and suprasegmental features such as prosody and speech rate that are currently poorly understood. For example, in a recent paper (Wilson, Abedduto, Camarata \& Shriberg, 2019), the Investigators describe cognitive/linguistic and speech-motor factors that relate to speech intelligibility in DS and provide preliminary data on nonphonemic parameters that are significantly correlated to intelligibility. In the cognitive linguistic domain, the Investigators found that measures of cognitive ability and receptive language abilities were directly related to speech intelligibility in people with DS. The Investigators also found that measures of speech-motor ability related to speech intelligibility. Importantly, in another series of studies, the Investigators demonstrated that individualized lexically based phonological recast intervention resulted in improvements in speech intelligibility in school age children with DS and that these gains were NOT uniquely attributable to changes in speech accuracy (phoneme production). Thus, the Investigators propose to induce growth in speech intelligibility in order to study change in speech and as an important step towards a) developing more effective speech interventions, and b) gaining a better understanding of parameters that drive improved speech intelligibility in DS (e.g.,phoneme production). This latter point is especially important because the Investigator's previous research and the extant literature indicate that traditional measures of speech accuracy (e.g., phoneme articulation) do not completely capture or predict improvements in speech intelligibility in DS. The proposed research would thus test assumptions underlying current models of speech disorder (and intervention) in DS. The Investigator's previous research has indicated that the Investigators can drive change in speech intelligibility without directly targeting speech accuracy, providing an opportunity to study intelligibility while controlling for speech accuracy as an untreated factor. Thus, an important first step in identifying factors that influence variation in speech intelligibility in addition to speech accuracy is to identify predictors of these speech abilities following intervention induced gains. Therefore, in keeping with the goals of an exploratory/developmental research project proposal (R21), the Investigators propose a pre-post design that measures speech intelligibility, and it's posited sequelae within the context of a controlled pre-post speech recast intervention study. Participants were 16 school-age children (4 to 17 years) with DS with varied cognitive ability levels (minimum of 60 with no ceiling). The following specific aims were pursued:

Aim 1: Test whether there were changes in baseline to post intervention measures of speech.

Aim 2: Examine the associations among measures of speech accuracy and prosody and overall speech intelligibility.

Impact: The results of this study within the context of a pre-post intervention design will provide important preliminary information on factors that contribute to intelligible speech in DS; thereby informing models of speech intelligibility and speech accuracy and future larger scale clinical trials. The proposed project will provide preliminary data to guide future longitudinal studies of value-added predictors of speech outcomes, and ultimately, improve assessment and intervention for speech deficits in individuals with DS.

Being tested
Lexically based speech recast

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lexically based speech recastBehavioural

    Also called Phonological Recast

    A child's spontaneous or elicited word production containing phonological errors is immediately followed with a clinician verbal model that corrects the error(s) at the word level rather than the isolated phoneme level. As an example, a speech recast of child's production of the word "bake" as [be] would be the whole lexeme bake [bek] rather than production drill on [k] in isolation.

Study groups in NCT05016037
Study groupRoleWhat they receive
Lexically Based Speech Intelligibility RecastOtherSpeech recasts are likely to improve speech intelligibility in Down Syndrome. The goal of this study is to induce change in speech intelligibility in order to study speech accuracy and prosody as predictors of change in speech intelligibility.
Receives: Behavioral: Lexically based speech recast

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Speech Intelligibility

    Speech intelligibility is a 5 point Likert scale based on the language sample obtained (e.g., based on the number of words spoken in the sample). The scale range is 1 to 5, 1 being very low intelligibility and 5 being high intelligibility.

    Measured: six months

  2. Speech Accuracy

    Percentage of correct phonemes on standardized speech tests and in a semi structured speech sample. This is the number of correct phonemes divided by the number of total phonemes in the sample (or test) divided by 100.

    Measured: six months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Aug 2021
  2. Study start14 Feb 2022
  3. Primary completion30 Apr 2024
  4. Study completion30 Apr 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
18 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05016037
Sponsor's protocol ID
Vanderbilt_UniversityMC
Other IDs
R21DC019280-01A1
Status last verified
Jul 2025
First submitted
17 Aug 2021
Last updated
3 Aug 2025
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Yoder PJ, Camarata S, Woynaroski T. Treating Speech Comprehensibility in Students With Down Syndrome. J Speech Lang Hear Res. 2016 Jun 1;59(3):446-59. doi: 10.1044/2015_JSLHR-S-15-0148.

    PubMed 27300156
  • Yoder PJ, Woynaroski T, Camarata S. Measuring Speech Comprehensibility in Students with Down Syndrome. J Speech Lang Hear Res. 2016 Jun 1;59(3):460-7. doi: 10.1044/2015_JSLHR-S-15-0149.

    PubMed 27299989
  • Wilson EM, Abbeduto L, Camarata SM, Shriberg LD. Speech and motor speech disorders and intelligibility in adolescents with Down syndrome. Clin Linguist Phon. 2019;33(8):790-814. doi: 10.1080/02699206.2019.1595736.

    PubMed 31221010

Questions about this trial

What is this clinical trial studying?

A study testing Lexically based speech recast in people with Speech Intelligibility Intervention in Down Syndrome, run by Vanderbilt University Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 3 Aug 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Speech Intelligibility (time frame: six months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05016037, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in